June 10, 2015
Authored and Edited by Elizabeth D. Ferrill; Michael Liu Su, Jeff T. Watson
In ArcelorMittal France v. AK Steel Corp., No. 14-1189 (Fed. Cir. May 12, 2015), the Federal Circuit affirmed the district court’s finding that certain claims of U.S. Patent No. RE44,153E (“the RE153 patent”) were invalid as impermissibly broadened, but reversed the district court’s determination of invalidity with respect to other claims that were not broadened.
The RE153 patent is a reissue of U.S. Patent No. 6,296,805 (“the ’805 patent”). In a previous appeal regarding the ’805 patent, the Federal Circuit affirmed the district court’s construction of a claim term and remanded the case. While that appeal was pending, ArcelorMittal sought to correct that construction through a reissue application, which led to the RE153 patent. On remand, ArcelorMittal substituted the ’805 patent for the RE153 patent. The district court granted summary judgment that all claims of the RE153 patent were invalid.
In the present appeal, the Federal Circuit held that the law-of-the-case doctrine prohibited the district court from revisiting its original construction; thus, it affirmed the district court’s finding that claims that were broadened in view of that construction were invalid. The Court also noted, however, that invalidity based on impermissible broadening must be analyzed on a claim-by-claim basis. Accordingly, the Court held that the district court erred in invalidating two claims that did not broaden the scope of the original claims.
Copyright © 2015 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a
§ 325(d) EPR Denial
May 28, 2026
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.